TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce its unaudited results as at and for the three and nine months ended March 31, 2025. As at March 31, 2025, the Company had cash, investments and digital assets of $37.4 million. As at March 31, 2025, net asset value per share w ...

CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- Magnera Corporation (NYSE: MAGN) today announced they will attend the 2025 Wells Fargo Industrials & Materials Conference in Chicago, Illinois. Magnera CEO, Curt Begle, and CFO & Treasurer, Jim Till, will present at the conference during a fireside chat on Wednesday, June 11th, 2025, at 3:45 p.m. CT. 1x1 meetings with institutional investors will take place June 11-12, 2025. A live webcast of the presentation will be available on the company's website at: ht ...

Core Insights - Volatus Aerospace Inc. reported Q1 2025 financial results, generating revenues of CAD 5,713,158 with a gross margin of 32% [2][6] - The company achieved a 30% year-over-year improvement in Adjusted EBITDA, reducing losses from CAD 1.39 million in Q1 2024 to CAD 978,000 in Q1 2025 [7][8] - The company is focusing on operational efficiency and strategic partnerships to enhance its market position and profitability [8] Financial Highlights - Revenue for Q1 2025 was CAD 5,713,158, down from CAD 6,623,741 in Q1 2024, reflecting a strategic repositioning towards a more profitable revenue mix [7][11] - Gross profit was CAD 1,829,973, with a gross margin of 32%, compared to 34% in Q1 2024, primarily due to a higher proportion of lower-margin equipment sales [7][11] - Comprehensive loss increased to CAD 4,285,320 in Q1 2025 from CAD 2,991,319 in Q1 2024, indicating ongoing challenges despite operational improvements [7][11] Operational Highlights - The company experienced a 47% quarter-over-quarter increase in equipment sales driven by changes in tariff policies in the US market [7] - Volatus closed a fully subscribed LIFE Offering of CAD 3,000,000 and a shares-for-debt transaction of CAD 2,646,000, strengthening its balance sheet [6][7] - The company announced several strategic partnerships to enhance its operational capabilities, including collaborations with Ondas Holdings and Draganfly for various projects [7][8] Regulatory and Market Developments - Volatus obtained Canada-wide approval for long-distance, remotely piloted BVLOS drone operations at night, which supports its expansion plans [7] - The company surpassed 75,000 flight hours in pipeline integrity monitoring, showcasing its operational experience and capabilities [7] - Ongoing geopolitical challenges are being navigated through diversification and securing key regulatory approvals [8]

Core Points - Zevra Therapeutics, Inc. announced the re-election of Wendy L. Dixon, Ph.D. and Tamara A. Favorito to its Board of Directors, serving until the 2028 Annual Meeting [1][2] - The Board expressed gratitude for stockholder participation and support, viewing the election results as a validation of their strategic direction and progress over the past two years [2][4] - Daniel J. Mangless attempted to nominate alternative candidates but failed to meet SEC proxy rules and the Company's bylaws, resulting in his nominations being disregarded [2][3] Company Strategy and Performance - The Board and management reaffirmed their commitment to driving growth and executing their strategic plan, focusing on creating long-term value for stockholders [2][4] - The election results indicated strong stockholder support for the Board's industry expertise and commitment to delivering value [4] Financial Oversight - Stockholders approved the appointment of Ernst & Young LLP as the independent auditors for the fiscal year ending December 31, 2025 [5] Company Overview - Zevra Therapeutics is a commercial-stage company dedicated to developing therapies for rare diseases, utilizing data-driven strategies to overcome drug development challenges [6]

Core Points - Cycurion, Inc. received a deficiency notification from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025 [1] - The notification does not have an immediate effect on the listing or trading of Cycurion's common stock on the Nasdaq Global Select Market [2] - The company has 60 days to submit a plan to regain compliance, with a potential extension of up to 180 days to meet the listing requirements [3] - The delay in filing the Form 10-Q is due to ongoing assessments, and the company is working diligently to complete the filing [4] Company Overview - Cycurion is based in McLean, Virginia, and specializes in IT cybersecurity solutions and AI, serving government, healthcare, and corporate clients [5] - The company utilizes its AI-enhanced ARx platform and expert team to provide secure and innovative services [5]

Core Viewpoint - Constellation Brands, Inc. will report its financial results for the first quarter ending May 31, 2025, on July 1, 2025, with a conference call scheduled for July 2, 2025, to discuss the results and future outlook [1][2]. Company Overview - Constellation Brands is a leading international producer and marketer of beer, wine, and spirits, with operations in the U.S., Mexico, New Zealand, and Italy [3]. - The company's mission focuses on building beloved brands and enhancing human connections, which drives its growth as one of the fastest-growing large consumer packaged goods (CPG) companies in the U.S. [3]. Product Portfolio - The company offers a range of high-end, iconic imported beer brands, including Corona Extra, Modelo Especial, and various craft spirits and fine wine brands such as The Prisoner Wine Company and Robert Mondavi Winery [4]. Sustainability and ESG Strategy - Constellation Brands emphasizes sustainable and responsible operations, integrating its Environmental, Social, and Governance (ESG) strategy into its business practices to support long-term goals [5].

EL DORADO HILLS, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Blaize Holdings, Inc. (NASDAQ: BZAI), a pioneer in scalable, energy-efficient AI computing across edge to cloud, today announced it will participate in the upcoming D.A. Davidson 1st Annual Consumer & Technology Conference on June 10, 2025, in Nashville, Tennessee. The conference will bring together public and private companies, institutional investors, and thought leaders across the consumer and technology landscape. Blaize will participate in a liv ...

HOUSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) announced today that it completed its regularly scheduled semi-annual borrowing base redetermination. The redetermination affirmed the borrowing base at $145 million. The next regularly scheduled borrowing base redetermination is expected to occur in the fourth quarter of 2025. Martyn Willsher, Amplify’s President and Chief Executive Officer commented, “I would like to express my appreciation to our synd ...

New York, NY, May 29, 2025 (GLOBE NEWSWIRE) -- Bowen Acquisition Corp (NASDAQ: BOWN) (“BOWN”), a special purpose acquisition company, announced that on May 28, 2025, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“NASDAQ”) advising the Company that the Company does not comply with NASDAQ’s Listing Rule 5250(c)(1) for continued listing because NASDAQ has not received the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2025 (the “Form ...

Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present novel research aimed at enhancing the clinical management of patients with cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being ...